Search > Chronic Lymphocytic Leukemia
My employer runs this trial

Nemtabrutinib + Venetoclax + Obinutuzumab for Chronic Lymphocytic Leukemia

MC
Overseen ByMedical College of Wisconsin Cancer Center Clinical Trials Office
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Medical College of Wisconsin
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a single-arm, open-label Phase 2 study designed to evaluate the treatment outcomes of nemtabrutinib-venetoclax-obinutuzumab as a frontline management for chronic lymphocytic leukemia (CLL).

Who Is on the Research Team?

GS

Guru S Guru Murthy, MD

Principal Investigator

Medical College of Wisconsin

Are You a Good Fit for This Trial?

This trial is for adults diagnosed with chronic lymphocytic leukemia (CLL) who have not yet received treatment. Participants should be healthy enough to undergo therapy and meet specific medical requirements set by the study team.

Inclusion Criteria

I am fully active or able to care for myself with minimal help.
My blood clotting tests are normal or controlled by medication.
Hematologic: Absolute Neutrophil Count (ANC) of at least 1000 and platelet count of at least 50,000 unless low due to bone marrow involvement by CLL/SLL (growth factors, transfusions allowed)
See 13 more

Exclusion Criteria

I have received anti-cancer drugs or trial treatments in the last month.
Positive urine pregnancy test within 72 hours prior to allocation for persons of childbearing potential; additional pregnancy test required if >72 hours between screening and first dose
Known allergy or sensitivity to nemtabrutinib or excipients
See 17 more

What Are the Treatments Tested in This Trial?

Interventions

  • Nemtabrutinib
  • Obinutuzumab
  • Venetoclax

Trial Overview

The study tests a combination of three drugs—nemtabrutinib, venetoclax, and obinutuzumab—as an initial treatment for CLL. All participants receive this combination in an open-label Phase 2 trial (everyone knows which drugs they are getting).

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Nemtabrutinib with Venetoclax and ObinutuzumabExperimental Treatment3 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Medical College of Wisconsin

Lead Sponsor

Trials
645
Recruited
1,180,000+

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.